TANG Ling, ZOU Limin, DU Yu, QI Yueli, XIANG Meiyi, YANG Zhimin. Current Development Status and Consideration for Rare Hemorrhagic Disease Drugs[J]. Journal of Rare Diseases, 2022, 1(4): 461-467. DOI: 10.12376/j.issn.2097-0501.2022.04.017
Citation: TANG Ling, ZOU Limin, DU Yu, QI Yueli, XIANG Meiyi, YANG Zhimin. Current Development Status and Consideration for Rare Hemorrhagic Disease Drugs[J]. Journal of Rare Diseases, 2022, 1(4): 461-467. DOI: 10.12376/j.issn.2097-0501.2022.04.017

Current Development Status and Consideration for Rare Hemorrhagic Disease Drugs

  • Hemophilia is the only rare hereditary hemorrhagic disorder included in the First Rare Diseases catalogue. However, rare bleeding diseases identified in the clinic are far more common than hemophilia. Most other rare hemorrhagic disorders have less effective treatment than hemophilia. Hemophilia has a history of successful drug development in rare hemorrhagic diseases, and the cycle between clinical research and drug development has been gradually realized. Drug research and pharmaceutical companies can refer to the drug research and development process in the field of hemophilia, learn from the experience of hemophilia drug research and develop treatments. The industry can increase drug development by strengthening basic research, focusing on the value of natural history research, the application of quantitative pharmacological tools and improving the efficiency of drug development to meet the urgent unmet medical needs of patients with rare hemorrhagic diseases.
  • loading

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return